BridgeBio’s Attruby (acoramidis) has the potential to be a highly competitive treatment for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) with its recent US Food and Drug Administration approval, thanks to the drug’s favorable labeling and lower price.
The FDA approved Attruby late on 22 November based on results from the Phase III ATTRibute-CM study, in which the drug, an orally administered TTR stabilizer, significantly reduced death and...
Key Takeaways
- The FDA approved BridgeBio’s Attruby for ATTR-CM with a label that includes both mortality benefits and the “near-complete” stabilization of TTR, a potential surrogate for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
